|
JAK Signaling in Depression and Cognition in Male Football Players
RECRUITINGPhase 2Sponsored by Emory University
Actively Recruiting
PhasePhase 2
SponsorEmory University
Started2026-10
Est. completion2027-10
Eligibility
Age30 Years – 55 Years
SexMALE
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT07608796
Summary
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.
Eligibility
Age: 30 Years – 55 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria: * willing and able to give written informed consent * males * playing tackle football for at least 11 years * 30-55 years of age * Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V * score of \>10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry * off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes) * CRP ≥3 mg/L * PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2 Exclusion Criteria: * current or history of past autoimmune disorder * history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection * history of any type of cancer requiring treatment with more than minor surgery * unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing) * significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000) * history of progressive multifocal leukoencephalopathy * history of deep venous thrombosis * history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK) * major surgery within 6 months before screening, or will require major surgery during the study * current or recent (\<4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection * symptomatic herpes zoster infection at or within 12 weeks of study start * history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement) * cirrhosis of the liver from any cause * Additional exclusion criteria apply
Conditions3
Cognitive SymptomDepressionDepressive Symptoms
Interventions1
Locations3 sites
Find trials near these locations
Related trials
- A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas — Assistance Publique - Hôpitaux de Paris
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Eli Lilly and Company
- ConsideRAte Study - Splenic Stimulation for RA — Galvani Bioelectronics
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) — Eli Lilly and Company
- Inflammation and Depression in People With HIV — Emory University
- JAK Signaling in Depression — Emory University
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institute of Allergy and Infectious Diseases (NIAID)
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorEmory University
Started2026-10
Est. completion2027-10
Eligibility
Age30 Years – 55 Years
SexMALE
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT07608796